Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

ONTX was reduced by  Zacks Research  from a “acquire” score to a “hold” score in a research note provided to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It focuses on uncovering as well as creating little molecule drug prospects to treat cancer. The Firm‘s products under different stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research analysts also recently commented on the company. Noble Financial reissued a “acquire” ranking as well as issued a $11.00 rate objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and established a “acquire” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day moving typical cost of $2.90 as well as a two-hundred day moving ordinary cost of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) revenues per share for the quarter, covering analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also an adverse net margin of 8,294.27%. The firm had income of $0.06 million throughout the quarter, contrasted to the consensus quote of $0.06 million. Throughout the same quarter in the previous year, the company published ($ 0.45) EPS. As a group, research analysts forecast that Onconova Therapeutics will certainly upload -1.18 EPS for the existing year.

A number of hedge funds have actually recently bought and sold shares of ONTX. GSA Funding Partners LLP bought a brand-new setting in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Management LP purchased a new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC purchased a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP got a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional capitalists own 13.36% of the company’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which takes part in the identification and growth of oncology therapeutics. It concentrates on discovering and creating tiny particle drug prospects to deal with cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a cost-free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

To learn more about research offerings from Zacks Investment Research, go to Zacks.com.

This immediate information alert was generated by narrative scientific research innovation and financial information from Market in order to provide viewers with the fastest as well as most exact coverage. This story was evaluated by Market’s editorial team prior to publication. 

 

SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?

Before you consider Onconova Therapeutics, you’ll wish to hear this.

Market tracks Wall Street’s top-rated as well as finest doing research experts as well as the stocks they advise to their clients each day. Market has actually identified the five stocks that top experts are quietly whispering to their clients to purchase now prior to the broader market catches on … and Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics presently has a “Buy” rating among analysts, premier experts believe these 5 stocks are much better acquires.

Scroll to top